Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1876)
Drug Name
LCZ-696
Synonyms
Entresto; Entresto (TN); LCZ 696; Sacubitril mixture with valsartan; Valsartan mixture with AHU-377; WB8FT61183; 3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate; 9052AF; AC-29037; ACN-036829; AK198922; C96H120N12Na6O21; D10226; EX-A2849; FT-0700025; MFCD29477717; Sacubitril valsartan sodium hydrate (JAN); UNII-WB8FT61183
Indication Myocardial infarction [ICD11: BA41] Phase 3 []
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 1916 Topological Polar Surface Area 396
Heavy Atom Count 135 Rotatable Bond Count 40
Hydrogen Bond Donor Count 7 Hydrogen Bond Acceptor Count 29
Cross-matching ID
PubChem CID
71449007
CAS Number
936623-90-4
TTD Drug ID
D0KQ8X
Formula
C96H120N12Na6O21
Canonical SMILES
CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
InChI
1S/2C24H29N5O3.2C24H29NO5.6Na.5H2O/c2*1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;2*1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;;;;;;;;/h2*6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);2*4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;;;;5*1H2/q;;;;6*+1;;;;;/p-6/t2*22-;2*17-,21+;;;;;;;;;;;/m0011.........../s1
InChIKey
ZASXKEGREHRXDL-CAWNUZPDSA-H
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Sacubitril DM003279
9811834
Hydrolysis - Ester hydrolysis 1 [2]
Valsartan DM003289
60846
Hydrolysis - Ester hydrolysis 1 [2]
LBQ657 DM003280
10430040
Hydrolysis - Ester hydrolysis 2 [3] , [4] , [2]
LCZ-696 Metabolite M2 DM003286 N. A. Unclear 2 [2]
LCZ-696 Metabolite M3 DM003288 N. A. Unclear 2 [2]
LCZ-696 Metabolite M4 DM003281 N. A. Unclear 3 [2]
LCZ-696 Metabolite M5 DM003282 N. A. Unclear 3 [2]
LCZ-696 Metabolite M6 DM003283 N. A. Oxidation - Oxidationn 3 [2]
LCZ-696 Metabolite M7 DM003284 N. A. Oxidation - Oxidationn 3 [2]
LCZ-696 Metabolite M8 DM003285 N. A. Unclear 3 [2]
LCZ-696 Metabolite M9 DM003287 N. A. Unclear 3 [2]
⏷ Show the Full List of 11  DM(s)
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR003714 LCZ-696 Sacubitril Hydrolysis - Ester hydrolysis Unclear [2]
MR003724 LCZ-696 Valsartan Hydrolysis - Ester hydrolysis Unclear [2]
MR003715 Sacubitril LBQ657 Hydrolysis - Ester hydrolysis Unclear [3], [4], [2]
MR003721 Sacubitril LCZ-696 Metabolite M2 Unclear Unclear [2]
MR003723 Sacubitril LCZ-696 Metabolite M3 Unclear Unclear [2]
MR003716 LBQ657 LCZ-696 Metabolite M4 Unclear Unclear [2]
MR003717 LBQ657 LCZ-696 Metabolite M5 Unclear Unclear [2]
MR003718 LBQ657 LCZ-696 Metabolite M6 Oxidation - Oxidationn Unclear [2]
MR003719 LBQ657 LCZ-696 Metabolite M7 Oxidation - Oxidationn Unclear [2]
MR003720 LBQ657 LCZ-696 Metabolite M8 Unclear Unclear [2]
MR003722 LCZ-696 Metabolite M2 LCZ-696 Metabolite M9 Unclear Unclear [2]
⏷ Show the Full List of 11 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[1]
References
1 FDA label of Sacubitril and valsartan. The 2020 official website of the U.S. Food and Drug Administration.
2 Disposition and metabolism of [(14)C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects
3 Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)
4 Dicarboxylic acid dipeptide neutral endopeptidase inhibitors

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.